Lineage Cell Therapeutics, Inc.

The current price of LCTX is $1.02 — it has increased by 3.75% since the previous close. Data as of Nov 6, 2026.

LCTX is up 0.99% over the past week, up 7.64% over the past month and down 42.05% over the past year. The price is below its 200-day moving average of $1.31.

Of the 7 analysts covering Lineage Cell Therapeutics, Inc., 1 rates it a strong buy, 5 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

Lineage Cell Therapeutics, Inc. has a market capitalization of $257.97M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Lineage Cell Therapeutics, Inc. posted a loss of $0.03 per share against an estimate of -$0.02833, missing expectations by 5.89%. Upcoming reports are listed in the earnings calendar.

Lineage Cell Therapeutics, Inc. reported revenue of $1.07M in its most recent quarter, which has decreased by 61.34% compared with the same quarter a year earlier. Analysts had expected $1.84M.

Lineage Cell Therapeutics, Inc. has not paid any dividends over the past year.

Companies most comparable to Lineage Cell Therapeutics, Inc. include Mesoblast Limited, Century Therapeutics, Inc. and Celularity Inc.

In the latest trading session LCTX moved between $0.9644 and $1.03, a range of 6.43% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Lineage Cell Therapeutics, Inc. shows a buy rating today and a sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Lineage Cell Therapeutics, Inc. is sell. Technical ratings are indicators, not investment advice.

Over the past 52 weeks LCTX has traded between $0.8823 and $1.99. The current price is 48.74% below its 52-week high.